Dr. Peters Named Head of the Michigan Cancer Foundation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

DETROIT--William P. Peters, MD, PhD, noted for pioneering outpatient ABMT for breast cancer at Duke University (see story on page 9), has been named president and CEO of the Michigan Cancer Foundation and director of the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit, effective July 1. He will also serve as associate dean for cancer programs at Wayne State University School of Medicine.

DETROIT--William P. Peters, MD, PhD, noted for pioneering outpatientABMT for breast cancer at Duke University (see story on page 9),has been named president and CEO of the Michigan Cancer Foundationand director of the Meyer L. Prentis Comprehensive Cancer Centerof Metropolitan Detroit, effective July 1. He will also serveas associate dean for cancer programs at Wayne State UniversitySchool of Medicine.

Articles in this issue
IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma
Dr. Peters Named Head of the Michigan Cancer Foundation
Broad-Spectrum Sunscreens Block UVA and UVB
Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca
Outpatient ABMT at Duke Leads to Savings
Russia Is Taking First Steps to Deliver Its Health-Care System Out of Chaos
Algorithm Optimizes Value of CA125 II Screening for Ovarian Ca
Better Ovarian Cancer Outcome With IP Cisplatin
Counseling Must Go Hand in Hand With Genetic Testing for Breast Cancer
Epirubicin Effective But Toxicity Is Increased
Aggressive 16-Week Multidrug Regimen Improves Breast Cancer Survival
Telomerase Appears to Play a Role in Cancer Cell Immortality
Changes in Health-Care Delivery Could Alter System of Medical Ethics
Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines
NIH Granted Gene Therapy Patent
Recent Videos
2 KOLs are featured in this series
2 KOLs are featured in this series
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Related Content
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD
July 24th 2024
Article
Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
July 24th 2024
Article

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

Telomere-Targeting Agent Demonstrates Tolerability in Advanced NSCLC

Roman Fabbricatore
July 23rd 2024
Article

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.

Nintedanib Does Not Significantly Improve PFS in Thyroid Cancer

Roman Fabbricatore
July 23rd 2024
Article

An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.